BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 16337493)

  • 1. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U
    Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
    Delorme S; Chiasson JL
    Curr Opin Pharmacol; 2005 Apr; 5(2):184-9. PubMed ID: 15780829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Does targeted therapy of type 2 diabetes prevent cardiovascular incidents?].
    Leschke M
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():12-6. PubMed ID: 14694836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden.
    Quilici S; Chancellor J; Maclaine G; McGuire A; Andersson D; Chiasson JL
    Int J Clin Pract; 2005 Oct; 59(10):1143-52. PubMed ID: 16178980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycaemic control is essential for effective cardiovascular risk reduction across the type 2 diabetes continuum.
    Karasik A
    Ann Med; 2005; 37(4):250-8. PubMed ID: 16019723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
    Liebl A
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():7-11. PubMed ID: 14694835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
    Chiasson JL
    Diabet Med; 1996; 13(3 Suppl 2):S23-4. PubMed ID: 8689858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
    Sakamoto N; Tajima N
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
    [No Abstract]   [Full Text] [Related]  

  • 10. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(2):377-9. PubMed ID: 15922116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
    Pistrosch F; Schaper F; Passauer J; Koehler C; Bornstein SR; Hanefeld M
    Horm Metab Res; 2009 Feb; 41(2):104-8. PubMed ID: 19061152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of acarbose in patients with beta-thalassaemia major and abnormal glucose homeostasis.
    Mangiagli A; Campisi S; De Sanctis V; Nicoletti MC; Cardinale G; Galati MC; Raiola G; Rigano P; Saviano A;
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():276-8. PubMed ID: 16462708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation.
    Azuma K; Toyofuku Y; Iesaki T; Otsuka A; Tanaka A; Mita T; Hirose T; Tanaka Y; Daida H; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2006 Jun; 345(2):688-93. PubMed ID: 16696939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.
    Hanefeld M; Schaper F
    Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):153-63. PubMed ID: 18248270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
    Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
    JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug therapy in prediabetes.
    Mukhopadhyay P; Chowdhury S
    J Indian Med Assoc; 2005 Nov; 103(11):603-5, 608. PubMed ID: 16570765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
    Kirkman MS; Shankar RR; Shankar S; Shen C; Brizendine E; Baron A; McGill J
    Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
    Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postprandial hyperglycaemia and vascular damage--the benefits of acarbose.
    Båvenholm PN; Efendic S
    Diab Vasc Dis Res; 2006 Sep; 3(2):72-9. PubMed ID: 17058626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
    Laakso M
    Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.